| Autor: |
Esteve, Maria, Temiño, Rocío, Carrasco, Anna, Batista, Lissette, Del Val, Adolfo, Blé, Michel, Santaolaria, Santos, Molina-Infante, Javier, Soriano, Germán, Agudo, Sandra, Zabana, Yamile, Andújar, Xavier, Aceituno, Montserrat, Ribes, Josepa, Madridejos, Rosa, Fernández-Bañares, Fernando |
| Zdroj: |
Digestive & Liver Disease; Feb2016, Vol. 48 Issue 2, p154-161, 8p |
| Abstrakt: |
Aims (1) Assess the population-based incidence of severe olmesartan-associated enteropathy. (2) To describe patients of the Spanish registry. (3) Evaluate markers of potential coeliac disease and associated autoimmunity. Methods Crude incidence rates in the area of Terrassa (Catalonia) were calculated. Clinical characteristics of patients in the Spanish registry were collected. Duodenal lymphocyte subpopulations and anti-TG2 IgA deposits were assessed in a subset of patients. Results Annual incidence rates (2011–2014) ranged from 0 to 22 cases per 10 4 treated patients. Twenty patients were included in the Spanish registry. Nineteen (95%) exhibited villous atrophy and 16 (80%) had severe enteropathy. Lupus-like disease occurred during olmesartan treatment in 3 patients. HLA-DQ2/DQ8 was positive in 64%. Markers of potential coeliac disease were present in 4 out of 8 patients (positive anti-TG2 deposits and/or increased CD3+gammadelta+ intraepithelial lymphocytes and reduced CD3−). Histopathological changes and clinical manifestations including autoimmune disorders improved after olmesartan discontinuation but not after gluten-free diet, irrespective of the presence or absence of coeliac markers. Conclusions Incidence of severe olmesartan-associated enteropathy was low. Autoimmune phenomena were present in a subset of cases and reversed after olmesartan removal. A genetic coeliac disease background and the presence of potential coeliac markers might uncover predisposing factors. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect